Altimmune, Inc. (NASDAQ:ALT) Q1 2020 Earnings Conference Call - Final Transcript
May 14, 2020 • 08:30 am ET
Thank you for standing by. This is the conference operator. Welcome to the Altimmune Incorporated First Quarter 2020 Earnings Conference Call. [Operator Instructions]
I would now like to turn the conference over to Monique Kosse of LifeSci Advisors. Please go ahead.
Thank you, operator, and thank you, everyone, for participating in today's first quarter 2020 earnings conference call.
Leading the way today will be Vipin Garg, Chief Executive Officer of Altimmune. Also participating on the call today is Will Brown, Chief Financial Officer; Scot Roberts, Chief Scientific Officer; and Scott Harris, Chief Medical Officer. After the prepared remarks, we will open up the call for a question-and-answer session. A press release with the first quarter 2020 financial results was issued last night and can be found on the Investors page of the company's website.
Before we begin, I would like to remind everyone that remarks about future expectations, plans and prospects constitute forward-looking statements for the purpose of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including those related to COVID-19 and its impact on our business operations, clinical trials and results of operations.
For a discussion of some of the risk factors that could affect the company's future results, please see the risk factors and other cautionary statements contained in the company's filings with the Securities and Exchange Commission. I would also direct you to read the forward-looking statement disclaimer in our earnings release issued last night and now available on our website.
Any statements made on this conference call speak only as of today's date, Thursday, May 14, 2020, and the company does not undertake any obligation to update any of these forward-looking statements to reflect events or circumstances that occur on or after today's date. As a reminder, this conference call is being recorded and will be available for audio rebroadcast on Altimmune's website at www.altimmune.com.
With that, I will now turn the call over to Vipin Garg, Chief Executive Officer of Altimmune. Vipin, please go ahead.
Vipin K. Garg
Thank you, Monique. Good morning, everyone, and thank you for joining us, as we discuss our Q1 2020 financial results and corporate update.
Joining me on the call today is Will Brown, our Chief Financial Officer, who will review our Q1 financial results; as well as Scott Harris, our Chief Medical Officer; and Scot Roberts, our Chief Scientific Officer. After our discussion, we will open the call for Q&A.
We have all watched, in recent months, the historic impact of COVID-19 on both our businesses and our personal lives. Our thoughts and prayers go out to all of those fighting this disease, including both our healthcare workers and those infected. Most of our employees continue to work remotely with the exception of our lab personnel who continue their important COVID-19 vaccine development work.
Despite operating under these conditions, we have made significant strides this